<DOC>
	<DOCNO>NCT02240693</DOCNO>
	<brief_summary>The study design compare effect 4 different dos orally administer BI 409306 placebo patient Alzheimers Disease</brief_summary>
	<brief_title>Alzheimer Disease Proof Concept Study With BI 409306 Versus Placebo</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Male female patient age least 55 year Body weight low 50 kgs Patients confirm diagnosis prodromal AD neuropsychological testing define : MiniMental State Examination ( MMSE ) score : great equal 24 global CDRscore 0 0.5 Free Cued Selective Recall Reminding Test ( FCSRT ) score : free recall test : low equal 20 ( 48 ) total recall test : low equal 42 ( 48 ) Patients reach require score FCSRT additionally perform Wechsler Memory Visual Paired Associates test . If Wechsler Memory Visual Paired Associates test show cognitive deficit bad 1 standard deviation mean ( compare reference value age educational norm inclusion ) , patient consider eligible study . Confirmation abnormal marker AD pathology either via ) , alternatively b ) mention : 1 . Presence cerebrospinal fluid ( sample take within past 4 month may eligible , : low Aß142 concentration ( &lt; 640 pg/mL ) increase total tau concentration ( &gt; 375 pg/ml ) , / low Aß142 concentration ( &lt; 640 pg/mL ) increase phosphotau concentration ( &gt; 52 pg/mL cerebrospinal fluid ) , 2 . Abnormal amyloid deposition cerebral PET scan . Scans perform past accoring recommendation protocol acceptable Patients receive prescribed drug treatment AD ( include acetyl cholinesterase inhibitor ( donepezil , galantamine , rivastigmine , tacrine , phenserine ) Memantine within three month prior screen Patients must least 6 year formal education fluency test language verbally confirm patient document study investigator . Patients must give write informed consent accordance Good Clinical Practice ( GCP ) local legislation prior study procedure . All patient must able give informed consent personally capacity consent . An informed consent give legal representative accept . Patients must reliable study partner ( per investigator judgement , instance family member , partner , guardian etc . ) Exclusion criterion : Mild cognitive impairment etiology prodromal AD ( example : neurosyphilis , craniocerebral trauma , small vessel disease ) base clinical data and/or current laboratory finding and/or preexist MRI CT brain ( CCT ) . If previous cranial imaging available old 12 month prior screen CCT MRI need perform screen Substantial concomitant cerebrovascular disease ( defined history stroke / intracranial haemorrhagia ) temporally relate onset worsen cognitive impairment per investigator judgement Medical history cancer ( except basal cell carcinoma ) and/or treatment cancer within last 5 year Medical history diagnosis symptomatic unstable/uncontrolled condition per investigator judgement Severe renal impairment define glomerular filtration rate ( GFR ) &lt; 30ml/min/1.73m2 screen central lab report Any psychiatric disorder schizophrenia , mental retardation Any suicidal action past 2 year ( per investigator judgement i.e . actual attempt , interrupt attempt , abort attempt , preparatory act behaviour ) Any suicidal ideation type 4 5 Columbia Suicide Severity Rating Scale ( CSSRS ) past 3 month ( i.e . active suicidal think intent without specific plan , active suicidal think plan intent ) Previous participation investigational drug study mild cognitive impairment within three month prior screen . Having receive active treatment study target disease modification like Aß immunization tau therapy . Previous participation study nonprescription medication , vitamin nutritional formulation allow . Significant history drug dependence abuse ( include alcohol , define Diagnostic Statistical Manual Mental Disorders [ DSMV ] opinion investigator ) within last two year , positive urine drug screen cocaine , heroin , marijuana . Known history HIV infection Any plan surgery require general anaesthesia , hospitalisation 1 day study period Premenopausal woman ( last menstruation &lt; = 1 year prior informed consent ) nursing pregnant childbearing potential practicing acceptable method birth control For male patient : Men able father child , unwilling abstinent use adequate form effective contraception duration study participation least 28 day treatment end . Use investigational drug procedure indication within 3 month 6 halflives ( whichever longer ) prior randomization . Intake follow medication within 3 month prior randomization intend initiated duration trial : 1. tricyclic antidepressant , 2. antidepressant monoamine oxidase inhibitor , 3. neuroleptic moderate great anticholinergic potency ( e.g . chlorpromazine , fluphenazine , loxapine , perphenazine , thioridazine ) , 4. anticholinergic medication The following drug may give need total daily dose stable 8 week prior randomisation expect duration trial : 1. neuroleptic list protocol 2. benzodiazepine sedative list protocol Clinically significant uncompensated hearing loss judgment investigator . Use hearing aid allow . Known hypersensitivity drug product excipients</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>